A Phase III, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML after ≥2 Prior TKIs

In this Phase III, open-label study, patients with chronic myeloid leukemia (CML) in chronic phase previously treated with ≥2 tyrosine kinase inhibitors (TKIs) were randomized to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily.